Navigation Links
Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET
Date:5/5/2011

ndocrine tumors of pancreatic origin (PNET) in patients with unresectable, locally advanced or metastatic disease. The safety and effectiveness of Afinitor in the treatment of patients with carcinoid tumors have not been established.

For more information visit www.AFINITOR.com/pNET or call 1-888-4-AFINITOR. US patients who may be eligible for financial assistance can learn about the Patient Assistance Now Oncology (PANO) reimbursement support program by contacting 1-800-282-7630 or visiting the Afinitor website.

Afinitor is approved in the US for the treatment of patients with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib and in the European Union (EU) for the treatment of patients with advanced RCC whose disease has progressed on or after treatment with vascular endothelial growth factor (VEGF)-targeted therapy.

Afinitor is also approved in the US to treat patients with subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis who require therapeutic intervention but are not candidates for curative surgical resection. The effectiveness of Afinitor is based on an analysis of change in SEGA volume. Clinical benefit such as improvement in disease-related symptoms or increase in overall survival has not been shown. Novartis has submitted marketing applications for everolimus for this use to the European Medicines Agency (EMA) and the Swiss Agency for Therapeutic Products (Swissmedic), and additional regulatory submissions are under way worldwide.

Afinitor is available in the US in 2.5 mg, 5 mg and 10 mg tablet strengths.

In the US, everolimus is available in different dosage strengths for the non-oncology patient population under the trade name Zortress® for the prophylaxis of organ rejection in adult patients at low-moderate immunologic risk receiving a kidney transplant. In the EU, everolimus is available in different
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin
2. US Supreme Court Denies Certiorari and Thereby Leaves in Place Second Circuit Ruling That Novartis Pharmaceuticals Corporation Must Pay its Sales Representatives Overtime Compensation
3. Novartis Gains FDA Approval for Amturnide™, a Triple-Combination Pill to Treat High Blood Pressure in Patients Uncontrolled on Two Medications
4. Study Shows Novartis Drug Afinitor® Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients
5. Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients
6. Phase III Data Published in Lancet Show Novartis Drug Zometa® Improves Overall Survival in Newly Diagnosed Multiple Myeloma Patients
7. Final Approval of Novartis Gender Discrimination Settlement Slated for November 19
8. Study in NEJM Shows Novartis Drug Afinitor® Reduces Size of SEGAs, Benign Brain Tumors Associated with Tuberous Sclerosis
9. VIDEO from thenewsmarket.com and Novartis: Novartis drug Afinitor® Approved by FDA as First Medication for Children and Adults With a Benign Brain Tumor Associated With Tuberous Sclerosis
10. Novartis to Expand Global Research Headquarters in Cambridge, MA
11. VIDEO From thenewsmarket.com and Novartis: Phase III Data Show That Novartis Meningococcal Vaccine Menveo® Demonstrated Robust Immunogenicity in Infants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014  A novel wearable injector slightly larger than ... for patients to self-inject prescription drugs in the large doses ... blood diseases, autoimmune deficiencies, and genetic disorders.  ... $220B by 2018, according to analysts.   Many of these drugs ...
(Date:1/14/2014)... HILLS, Calif. , Jan. 14, 2014 The Brandeis Medical ... Los Angeles a premier and affordable laser tattoo removal ... special. Dr. Brandeis, focus is in providing high quality cosmetic services ... all patients. " Southern California has ...
(Date:1/14/2014)... Jan. 14, 2014   NuAire , a manufacturer of ergonomically designed ... Hitachi Koki of Japan to ... North America . NuAire will utilize its network of sales ... Canada to offer assistance in application use, product ...
Breaking Medicine Technology:Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2NuAire announces sales and service of Hitachi Koki centrifuges in North America 2
... Amarin Corporation plc (Nasdaq: AMRN ) ... on cardiovascular disease, today announced that, in connection with ... Shares ("ADSs"), the underwriters of the offering have exercised ... aggregate of 1,800,000 additional ADSs to cover over-allotments.  The ...
... 7, 2011 Echo Therapeutics, Inc. (OTC Bulletin Board: ... Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous ... transdermal drug delivery, today announced that Patrick T. Mooney, ... Echo Therapeutics will present at the OneMedForum 2011 annual ...
Cached Medicine Technology:Amarin Announces Underwriters' Exercise of Over-Allotment Option 2Amarin Announces Underwriters' Exercise of Over-Allotment Option 3Amarin Announces Underwriters' Exercise of Over-Allotment Option 4Echo Therapeutics to Present at the OneMedForum 2011 Conference 2
(Date:4/17/2014)... Scientists have identified the first genetic variant specifically ... sub-type accounting for around 10-15 per cent of ... study of the breast cancer sub-type, called invasive ... genetic causes of this particular kind of breast ... The research, published today (Thursday) in the journal ...
(Date:4/17/2014)... Experimental Biology and Medicine a multidisciplinary ... Paul Kenis in the Institute of Genomic Biology ... Illinois Urbana-Champaign describe their recent work on subcellular ... of cell functions including energy metabolism, signaling, and ... regulating normal cellular behavior, redox status has been ...
(Date:4/17/2014)... MD, was recently invited to submit a review ... Microbiology , one of the world,s foremost scientific ... specialist, and chair of the Department of Pediatrics ... analyzed the epidemiology and microbiology of co-infections during ... as more recent 2009 novel H1N1 pandemic. ...
(Date:4/17/2014)... as many as 10 million older Americans suffer from ... isolation. , However, new research a project that ... for six years found that Internet use among ... more than 30 percent. , "That,s a very strong ... of telecommunication, information studies and media who led the ...
(Date:4/17/2014)... from Boston University School of Medicine (BUSM) have ... consumption in an experimental model. The findings, reported ... Alcohol Abuse , may lead to more effective ... is one of the leading causes of illness ... negative economic impact by limiting the productivity of ...
Breaking Medicine News(10 mins):Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:Internet use can help ward off depression among elderly 2Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2
... SAN DIEGO, Feb. 4 SpectraScience, Inc. (OTC Bulletin ... announced today that it has entered into a $6.0 ... II, LLC, a Chicago-based institutional investor. Under the ... of its common stock to Fusion Capital from time ...
... technology startup has been selected to participate in ... WEC25 Expo is an opportunity for entrepreneurs to ... network of VCs and entrepreneurs. Delfigo Security,s patent-pending ... access management industry to offer a rich ...
... Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV ) (the "Company") ... quarter of fiscal 2009, ended December 31, 2008. The Company ... of $7.6 million or $0.10 per share for the quarter ... $16.4 million and a consolidated net loss of $14.7 million ...
... Feb. 4 "Physician Hospitals of America (PHA) ... bill which will provide healthcare access and insurance ... PHA Executive Director. "Congress recognized that the ... passage in order to address the contentious issue ...
... Young Innovations, Inc.,(Nasdaq: YDNT ) today announced ... Sales for the fourth quarter of ... from the $25.0 million reported in the fourth quarter,of 2007. ... the,fourth quarter of 2007 to $4.8 million in the fourth ...
... Elton John AIDS Foundation announced today that Grammy-nominated artist ... John AIDS Foundation (EJAF) Academy Awards(R) Viewing Party on ... in Los Angeles. The event will be co-hosted by ... co-sponsored by Chopard, Jo & Raffy Manoukian, and Vh1.Oakland ...
Cached Medicine News:Health News:SpectraScience, Inc. Enters Into $6.0 Million Common Stock Purchase Agreement 2Health News:SpectraScience, Inc. Enters Into $6.0 Million Common Stock Purchase Agreement 3Health News:Delfigo Security Selected as One of Twenty Five Most Promising Startups by The Wharton Entrepreneurship Conference 2Health News:Delfigo Security Selected as One of Twenty Five Most Promising Startups by The Wharton Entrepreneurship Conference 3Health News:Indevus Pharmaceuticals Announces First Quarter Fiscal 2009 Financial Results 2Health News:Indevus Pharmaceuticals Announces First Quarter Fiscal 2009 Financial Results 3Health News:Indevus Pharmaceuticals Announces First Quarter Fiscal 2009 Financial Results 4Health News:Indevus Pharmaceuticals Announces First Quarter Fiscal 2009 Financial Results 5Health News:Indevus Pharmaceuticals Announces First Quarter Fiscal 2009 Financial Results 6Health News:Indevus Pharmaceuticals Announces First Quarter Fiscal 2009 Financial Results 7Health News:Indevus Pharmaceuticals Announces First Quarter Fiscal 2009 Financial Results 8Health News:Physician Hospitals of America (PHA) Congratulates Congress on its Passage of a 'Clean' SCHIP Children's Health Bill 2Health News:Young Innovations, Inc. Announces Results for 4th Quarter and the Year and Declares Dividend 2Health News:Young Innovations, Inc. Announces Results for 4th Quarter and the Year and Declares Dividend 3Health News:Young Innovations, Inc. Announces Results for 4th Quarter and the Year and Declares Dividend 4Health News:Young Innovations, Inc. Announces Results for 4th Quarter and the Year and Declares Dividend 5Health News:Young Innovations, Inc. Announces Results for 4th Quarter and the Year and Declares Dividend 6Health News:Young Innovations, Inc. Announces Results for 4th Quarter and the Year and Declares Dividend 7Health News:Three-Time Grammy Nominee Raphael Saadiq to Perform at 17th Annual Elton John AIDS Foundation Academy Awards(R) Viewing Party 2Health News:Three-Time Grammy Nominee Raphael Saadiq to Perform at 17th Annual Elton John AIDS Foundation Academy Awards(R) Viewing Party 3Health News:Three-Time Grammy Nominee Raphael Saadiq to Perform at 17th Annual Elton John AIDS Foundation Academy Awards(R) Viewing Party 4
Unique criss-cross strapping. The MSV-10 is our most popular model. Extra wide Velcro ensures a wide variety of adjustments and easy closing....
Six inch wide elastic belt transfers the apron weight off the shoulders. 0.5mm front and 0.25mm back with a generous overlap for double protection. Shoulder pads included. Also available without wide...
6" wide elastic belt transfers the apron weight off the shoulders to the hips making this apron the most comfortable for long procedures. Adjustable. Velcro keeps apron snug....
... single-use, direct current stimulator ... 0.5, 1.0, and 2.0mA ... needle as the grounding ... flow" confirmation light is ...
Medicine Products: